Oxidized lipids enhance RANKL production by T lymphocytes: implications for lipid-induced bone loss.
Osteoporosis is a systemic disease that is associated with increased morbidity, mortality and health care costs. Whereas osteoclasts and osteoblasts are the main regulators of bone homeostasis, recent studies underscore a key role for the immune system, particularly via activation-induced T lymphocyte production of receptor activator of NFkappaB ligand (RANKL). Well-documented as a mediator of T lymphocyte/dendritic cell interactions, RANKL also stimulates the maturation and activation of bone-resorbing osteoclasts. Given that lipid oxidation products mediate inflammatory and metabolic disorders such as osteoporosis and atherosclerosis, and since oxidized lipids affect several T lymphocyte functions, we hypothesized that RANKL production might also be subject to modulation by oxidized lipids. Here, we show that short term exposure of both unstimulated and activated human T lymphocytes to minimally oxidized low density lipoprotein (LDL), but not native LDL, significantly enhances RANKL production and promotes expression of the lectin-like oxidized LDL receptor-1 (LOX-1). The effect, which is also observed with 8-iso-Prostaglandin E2, an inflammatory isoprostane produced by lipid peroxidation, is mediated via the NFkappaB pathway, and involves increased RANKL mRNA expression. The link between oxidized lipids and T lymphocytes is further reinforced by analysis of hyperlipidemic mice, in which bone loss is associated with increased RANKL mRNA in T lymphocytes and elevated RANKL serum levels. Our results suggest a novel pathway by which T lymphocytes contribute to bone changes, namely, via oxidized lipid enhancement of RANKL production. These findings may help elucidate clinical associations between cardiovascular disease and decreased bone mass, and may also lead to new immune-based approaches to osteoporosis.
Graham
Lucia S
LS
Department of Pathology and Laboratory Medicine, David Geffen School of Medicine at UCLA, 10833 Le Conte Avenue, Los Angeles, CA 90095-1732, USA.
Parhami
Farhad
F
Tintut
Yin
Y
Kitchen
Christina M R
CM
Demer
Linda L
LL
Effros
Rita B
RB
D000818:Animals; D015519:Bone Density / Q000187:drug effects; D001862:Bone Resorption / Q000139:chemically induced* / Q000378:metabolism; D002467:Cell Nucleus / Q000378:metabolism; D004041:Dietary Fats / Q000008:administration & dosage / Q000494:pharmacology; D015232:Dinoprostone / Q000031:analogs & derivatives / Q000494:pharmacology; D015870:Gene Expression / Q000187:drug effects / Q000235:genetics; D006801:Humans; D028421:Isoprostanes / Q000494:pharmacology; D008055:Lipids / Q000494:pharmacology*; D008077:Lipoproteins, LDL / Q000494:pharmacology; D008297:Male; D051379:Mice; D008810:Mice, Inbred C57BL; D016328:NF-kappa B / Q000037:antagonists & inhibitors / Q000378:metabolism; D053244:Osteoprotegerin / Q000235:genetics; D010084:Oxidation-Reduction; D010713:Phosphatidylcholines / Q000494:pharmacology; D053245:RANK Ligand / Q000097:blood / Q000235:genetics / Q000378:metabolism*; D051127:Scavenger Receptors, Class E / Q000235:genetics / Q000378:metabolism; D013601:T-Lymphocytes / Q000187:drug effects / Q000378:metabolism*; D051996:Transcription Factor RelA / Q000378:metabolism
D004041:Dietary Fats; D028421:Isoprostanes; D008055:Lipids; D008077:Lipoproteins, LDL; D016328:NF-kappa B; C495137:OLR1 protein, human; D053244:Osteoprotegerin; D010713:Phosphatidylcholines; D053245:RANK Ligand; D051127:Scavenger Receptors, Class E; C505688:TNFSF11 protein, human; D051996:Transcription Factor RelA; C099252:oxidized low density lipoprotein; C472349:oxidized-L-alpha-1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphorylcholine; D015232:Dinoprostone; C011987:8-isoprostaglandin E2
Circ Res. 2002 Aug 23;91(4):281-91
12193460
Am J Ophthalmol. 2009 Apr;147(4):571-2
19327444
Biochem J. 1999 Jan 15;337 ( Pt 2):269-74
9882624
J Rheumatol. 2004 Aug;31(8):1483-90
15290725
Cell. 1998 Apr 17;93(2):165-76
9568710
Nature. 1997 Mar 6;386(6620):73-7
9052782
JAMA. 2001 Aug 8;286(6):669-70
11495608
Annu Rev Immunol. 2006;24:33-63
16551243
Biochem Soc Trans. 2001 May;29(Pt 2):358-62
11356183
Cell. 2008 Jul 11;134(1):97-111
18614014
Curr Osteoporos Rep. 2008 Jun;6(2):67-71
18778566
Atherosclerosis. 2009 Aug;205(2):620-5
19230891
Nephrology (Carlton). 2006 Dec;11(6):506-9
17199788
Calcif Tissue Int. 1998 Mar;62(3):209-13
9501953
Clin Exp Rheumatol. 2007 Jul-Aug;25(4):605-12
17888218
Eur J Clin Invest. 1994 Dec;24(12):813-7
7705375
J Biol Chem. 2002 Apr 19;277(16):14221-6
11827970
J Clin Invest. 2008 Aug;118(8):2917-28
18636118
Lancet. 2000 Jun 24;355(9222):2218-9
10881898
Clin Cardiol. 2004 Nov;27(11):641-4
15562935
Arterioscler Thromb Vasc Biol. 2006 May;26(5):1169-76
16484596
Endocr Regul. 1993 Jun;27(2):57-60
8003710
J Leukoc Biol. 1999 Jun;65(6):715-24
10380891
J Exp Med. 2007 Feb 19;204(2):441-52
17296788
Eur J Immunol. 2008 Mar;38(3):778-87
18266300
J Clin Invest. 1989 Oct;84(4):1086-95
2794046
Atherosclerosis. 1985 Oct;57(1):65-73
3841001
Biol Pharm Bull. 2008 Aug;31(8):1475-82
18670075
J Thromb Thrombolysis. 2008 Oct;26(2):113-8
17963022
Blood. 2002 Jan 1;99(1):199-206
11756172
Heart. 2008 Sep;94(9):1111-2
18703687
Antioxid Redox Signal. 2003 Apr;5(2):163-9
12716476
Lancet. 2002 Jun 1;359(9321):1929-36
12057569
Arterioscler Thromb Vasc Biol. 2006 Apr;26(4):864-70
16456097
JAMA. 2000 Jun 28;283(24):3205-10
10866867
Biochem Pharmacol. 1996 Jan 12;51(1):1-9
8534261
Arterioscler Thromb Vasc Biol. 1997 Apr;17(4):680-7
9108780
Nature. 1999 Nov 18;402(6759):304-9
10580503
J Clin Invest. 1955 Sep;34(9):1345-53
13252080
Clin Rheumatol. 1994 Dec;13(4):611-4
7697964
Stroke. 1997 Sep;28(9):1730-2
9303016
FEMS Immunol Med Microbiol. 2002 Sep 6;34(1):45-50
12208605
J Bone Miner Res. 1999 Dec;14(12):2067-78
10620066
Proc Natl Acad Sci U S A. 1998 Mar 31;95(7):3597-602
9520411
J Biol Chem. 1997 Aug 22;272(34):20963-6
9261091
J Biol Chem. 1997 Oct 3;272(40):25190-4
9312132
Cardiovasc Drug Rev. 2007 Summer;25(2):146-61
17614937
J Histochem Cytochem. 2008 Aug;56(8):773-84
18474940
FEBS Lett. 1998 Nov 27;440(1-2):29-32
9862418
Lancet. 1991 Aug 10;338(8763):355-8
1677708
Scand J Immunol. 1996 Apr;43(4):381-4
8668916
J Bone Miner Res. 2007 Mar;22(3):465-75
17144789
J Bone Joint Surg Br. 1963 Aug;45:572-81
14058338
Cancer Lett. 2007 Dec 8;258(1):31-7
17868983
N Engl J Med. 1998 Dec 31;339(27):1972-8
9869668
J Immunol Methods. 1995 Jul 17;184(1):39-51
7622868
Circulation. 2003 Dec 16;108(24):2993-9
14638538
J Immunol. 2005 Jul 1;175(1):501-8
15972685
Cell Mol Biol (Noisy-le-grand). 2007;53 Suppl:OL954-64
17695085
Annu Rev Immunol. 2002;20:795-823
11861618
Biol Res. 2000;33(2):89-96
15693275
Am J Med. 1999 Mar;106(3):273-8
10190374
JAMA. 2004 Sep 15;292(11):1326-32
15367554
Ann N Y Acad Sci. 1993 Mar 15;676:297-307
8489141
Int J Mol Med. 2003 Jan;11(1):17-21
12469211
Calcif Tissue Int. 1996 Nov;59(5):352-6
8849401
J Bone Miner Res. 2008 Oct;23(10):1672-9
18505371
Nature. 2000 Nov 30;408(6812):535-6
11117729
Ann N Y Acad Sci. 2001 Dec;947:199-205; discussion 205-6
11795267
J Clin Densitom. 2007 Oct-Dec;10(4):376-80
17888698
Circulation. 2003 May 6;107(17):2181-4
12719282
Calcif Tissue Int. 2003 Jul;73(1):15-20
14506949
J Bone Miner Res. 2001 Jan;16(1):182-8
11149483
Arterioscler Thromb Vasc Biol. 2004 Feb;24(2):e6-10
14670933
Prostaglandins Leukot Essent Fatty Acids. 2003 Jun;68(6):373-8
12798657
JAMA. 2001 Jul 18;286(3):327-34
11466099
Biochem Biophys Res Commun. 2003 Mar 28;303(1):247-50
12646194
Proc Natl Acad Sci U S A. 1987 Jun;84(11):3763-7
3473481